Pinned Tweet
ECGs are one of those essential skills that take many years to develop a deep physiological understanding of and intuition for.
That's why @claudeai and I have built Dipole. A free 3D simulator and atlas for medical residents to do just that, faster.
dipoleecg.com
Talal Warsi, MD retweeted
Over the past week, I’ve been overwhelmed by the love and support of friends, industry colleagues, and people I've never met. Thank you to everyone who has shown kindness to my family and me. It means the world to me.
I came to the United States 53 years ago, and becoming an American citizen is one of the greatest gifts and proudest moments of my life. NVIDIA has been my life’s work. Building it into the company it is today alongside my colleagues has been a privilege and an honor. Nowhere but in America could a company like NVIDIA be possible. I love our country, and I love NVIDIA.
I did not live up to the standards expected of everyone at NVIDIA, and I have made serious mistakes in my personal life. I created problems for the Board that I deeply regret. I own my mistakes completely, and I am committed to cooperating with the Board’s independent investigation.
Since my departure, I’ve seen an outpouring of calls from NVIDIA’s employees, investors, business partners, and customers for me to return as CEO. Many continue to reach out to me directly as the company navigates complex technology, market, competitive, and geopolitical dynamics. NVIDIA is a once-in-a-generation company. If the Board of Directors decides that my return is in the best interest of our shareholders, our employees, the company, and America, I would be honored to answer these calls and return as CEO.
Thank you again to everyone who has shared their good wishes. I am profoundly humbled by your support. To my family: I love you, and I will spend the rest of my life being worthy of yours.
Jensen
Two CAMEO-SEMA papers worth reading together
Invasive: exercise PAWP -10.6 mmHg vs placebo
CMR substudy (n=49): LA reservoir strain +5.7% (95% CI +0.3 to +9.7), lower LV mass
Small, mechanistic, no hard outcomes, but a coherent picture of unloading in obesity-related HFpEF
Semaglutide (Ozempic) improved left atrial and diastolic function in a randomized trial of patients with preserved ejection fraction heart failure (HFpEF) and obesity (via MRI)
And achieved remission of symptoms in more than half of participants (2nd link)
#AHA26 and @NatureMedicine
nature.com/articles/s41591-0…
nature.com/articles/s41591-0…
2
44
I wonder if a dermatologist led this study 👀
The authors analyze the degree to which clinical specialties are shielded from, or threatened by, AI depending on how much of their work requires in-person physical interaction. Learn more: nejm.ai/3UDkrIv

ALT Bar chart titled "Limits to AI Substitution across Specialties: Composition of Medicare Part B Payments Including E&M Services." The chart shows percentages of "Physical," "E&M," and "Nonphysical" services across 15 medical specialties and all overall (US$44.9bn). Total 2023 Medicare Part B payments are shown in parentheses (US$ bn); amounts are in billions of U.S. dollars.
96
SYNCHRONIZE-CVOT did its job, Survodutide was noninferior for MACE
The story is tolerability, about 1 in 5 on either dose stopped for GI effects vs 1.9% on placebo, most during dose escalation
Rigid titration might be the real side effect? SYNCHRONIZE-START might make it clear
1
42
The OPTIMAL trials
Two trials, same targets (<120 vs <140), same ~13 mmHg gap achieved in BP
After stroke/TIA, HR 0.79 (0.67-0.94)
In diabetes, HR 0.90 (0.77-1.06)
The diabetes trial had half the event rate, and its CI still holds 0.79.
Maybe BP targets should follow risk, not diagnosis.
30
Excellent commentary by @drjohnm on OptimPacing, why a number doesn't tell the whole story
Few are bigger evangelists for conduction system pacing than me
But. But… These results—despite NEJM publication—do not settle the RV vs LBB pacing. I wrote about it here:
medscape.com/viewarticle/bes…
What the biggest medical breakthroughs will be according to @Claude Fable 5.2.
Realistic?
One iron infusion moved peak VO2 IN HFpEF by 1.1ml/kg/min vs placebo, plus 41m on the walk test. Haemoglobin up 1.4g/dL with peak HR unchanged, looks like more oxygen carried, not necessarily a fitter heart, which should matter for who gets it
IRONMET-HFpEF trial: one infusion of ferric derisomaltose was well tolerated and improved peak oxygen uptake at 12 weeks in iron-deficient patients with HFpEF, demonstrating evidence of improved exercise capacity.
Download slides here: clinicaltrialresults.org/wp-…
AI tools don't just invent references.
They give you real papers with someone else's PMID, or a real trial attached to a number it never reported.
I built a free tool that checks every reference against PubMed, CrossRef and 3 other databases.
github.com/WarsiMD/citation-…
2
2
76
Four skills in one, all designed to find and verify what you need and never ship anything without you verifying.
1
43
ADAPT AF-DES
The bleeding result is convincing major bleeding 10.6% vs 22.0%
The one number I'd watch is ischaemic stroke, 8 vs 3 events (HR 2.64, CI 0.70–9.97), probably noise with numbers that small
Still, it's getting hard to justify routine dual therapy at 1 year +
Presented at #TCT2026:
In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel. Full ADAPT AF-DES trial results: nej.md/4yOOTgK
@crfheart

ALT A table shows the clinical end points at 2 years. Columns include "End Point," "NOAC Monotherapy (N = 482)," "Combination Therapy (N = 478)," and "Hazard Ratio (95% CI)." "End Point" column lists the primary end point and secondary end points. The second and third columns have the number of patients and the percentage.
SIMPLAAFY in JAMA
What to give after an uncomplicated LAA closure, 1857 patients randomised to 3 regimens
Death, stroke, systemic embolism or major bleeding at 6 months was 6.9% with DAPT, 5.1% with reduced-dose NOAC and 3.3% with aspirin alone
1
60
Both simpler options were noninferior to DAPT
Major bleeding was 4.5%, 2.7% and 1.7%, and 45-day device-related thrombus 3.4%, 0.9% and 2.7%. Both are exploratory, so I wouldn't read them as proven differences
US-only, open-label, 6-month follow-up
1
1
44
After an uncomplicated closure, who still needs more than aspirin?
jamanetwork.com/journals/jam…
1
17
PROGRESS in NEJM
TAVR vs clinical surveillance in moderate aortic stenosis with at-risk features, 744 patients
Death or heart-failure event at 2 years was 16.7% with TAVR vs 23.9% with surveillance (risk difference −7.2 points, 95% CI −13.1 to −1.3)
1
55
That's about 1 event avoided per 14 treated over 2 years
All-cause death was 8.4% vs 7.3%. The gap comes from heart-failure events, 10.8% vs 19.0%
Open-label, mean age 78, transfemoral balloon-expandable valve only, Edwards-funded
1
36
I think the real comparison is TAVR now vs replacement later, since 57.4% of the surveillance group had one within 2 years anyway
Would this change how often you re-echo and refer moderate AS once symptoms or LV changes appear?
doi.org/10.1056/NEJMoa260732…
9





















